{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-036819","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.353666+00:00","generated_at":"2026-05-24T23:46:15.671202+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Q32 Bio Q4 2024 net loss $14.2M; cash $78M funds into 2H2026; bempikibart AA data encouraging","bullets":["Cash and cash equivalents $78.0M as of Dec 31, 2024, expected to fund operations into 2H'26.","Net loss $14.2M ($1.16 per share) for Q4 2024 vs $27.1M ($76.39) in Q4 2023.","SIGNAL-AA Part B dosing on track for 1H'25; topline data expected 1H'26.","Phase 2a Part A data presented at AAD showed durable responses post-treatment (median follow-up 41 weeks).","Bempikibart well-tolerated; no grade 3+ related AEs or related viral infections."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-036819","json":"https://secwatch.observer/filing/0000950170-25-036819.json","markdown":"https://secwatch.observer/filing/0000950170-25-036819.md","text":"https://secwatch.observer/filing/0000950170-25-036819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025036819/0000950170-25-036819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025036819/qttb-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:46:15.671202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}